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A synthetic method to prepare a core-shell-structured Fe3O4@SiO2 as a safe nanovehicle for tumor cell targeting
has been developed. Superparamagnetic iron oxide is encapsulated inside nonporous silica as the core to provide
magnetic targeting. Carboxymethyl chitosan-folic acid (OCMCS-FA) synthesized through coupling folic acid (FA)
with OCMCS is then covalently linked to the silica shell and renders new and improved functions because of the
original biocompatible properties of OCMCS and the targeting efficacy of FA. Cellular uptake of the nanovehicle
was assayed by confocal laser scanning microscope using rhodamine B (RB) as a fluorescent marker in HeLa cells.
The results show that the surface modification of the core-shell silica nanovehicle with OCMCS-FA enhances the
internalization of nanovehicle to HeLa cells which over-express the folate receptor. The cell viability assay demonstrated
that Fe3O4@SiO2-OCMCS-FA nanovehicle has low toxicity and can be used as an eligible candidate for drug delivery
system. These unique advantages make the prepared core-shell nanovehicle promising for cancer-specific targeting
and therapy.
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Recently, considerable effort has been devoted to mag-
netic nanoparticles (NPs) as novel nanovehicles [1] and
targeting agents [2] for biological and biomedical appli-
cations [3,4]. Iron oxide (Fe3O4) has emerged as one of
the appealing candidates for drug delivery system [5] and
magnetic fluorescence imaging [6,7]. However, the aggre-
gations of naked Fe3O4 NPs decrease their interfacial
areas, thus resulting in the loss of magnetism [8] and
dispersibility [9]. Therefore, extensive work has been done
to stabilize the NPs [10,11]. Huang synthesized uniform
Fe3O4@SiO2 NPs with well-controlled shell thickness [12].
Kaskel developed a homogeneous Fe3O4@SiO2 with hol-
low mesoporous structure for drug delivery [13]. Unfortu-
nately, the common challenge among these applications is
to ensure sufficient uptake of NPs by specific cells [14,15].
The outer shell of silica not only protects the inner* Correspondence: zwy_1115@126.com
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in any medium, provided the original work is pmagnetite core from aggregation [16,17] but also provides
sites for flexible surface modification such as poly(ethylene
glycol) to render NP biocompatibility by preventing the
nonspecific adsorption of proteins [18] and various tar-
geting biomolecules [19,20] to improve the targeting effi-
ciency. Kim reported Fe3O4@SiO2 NPs using CTAB as a
template and PEG to prolong the short blood half-life of
NPs [21]. However, the safety of drug carriers is one of
the most critical factors to ensure its efficacy. Carboxy-
methyl chitosan (OCMCS) is a water-soluble chitosan
which receives a great deal of interest because of favo-
rable biocompatibility, safety, nonimmunogenicity, as
well as reasonable cost [22]. Shi reported the OCMCS-
Fe3O4 easily internalized into cells via endocytosis [23].
Fan developed the Fe3O4 NPs with OCMCS which signifi-
cantly reduced the cytotoxicity and the capture of NPs.
Moreover, folic acid (FA)-modified OCMCS-Fe3O4 NPs
combined receptor-mediated targeting and magnetic tar-
geting together [24]. It is noted that folic acid, as an effect-
ive target ligand [25,26], shows high binding affinity with
folate receptor, which over-expressed on the membranes
of many human malignant cells, but limited on the normalen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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protocols to combine silica with diverse functional modi-
fication used as a safe drug delivery system are seldom
reported. With regard to the above effects, we develop a
novel carboxymethyl chitosan-based, silica-coated iron
oxide nanovehicle (Fe3O4@SiO2-OCMCS-FA) with dual-
targeting function (magnetic/folate) in this study. Fe3O4
core serves as a carrier for magnetic targeting, while silica
coating on the iron oxide NPs offers sites for further
modifications. OCMCS-FA was conjugated firstly to
perform a folate receptor (FR)-mediated cellular endo-
cytose and acted as the biocompatible segment and
then subsequently coupled through acylation to the
surface of animated Fe3O4@SiO2 which was modified
with (3-aminopropyl) triethoxysilane (APTES) to obtain the
multifunctional nanovehicle (Fe3O4@SiO2-OCMCS-FA).
Its uptake by human cervical carcinoma cell lines (HeLa
cells) is traced, and the cytotoxicity on the human tumor
cells and normal cells are both evaluated. The results
show that it is nontoxic to them, which reveal that it




All chemicals are analytical reagent grade and were used
as received. Folic acid is a biological reagent purchased
from Sinopharm Chemical Reagent Co., Ltd., Shanghai,
China.
Synthesis of magnetic Fe3O4@SiO2 NPs
Monodispersed Fe3O4 NPs were prepared by the thermal
decomposition of ferric acetylacetonate precursor in the
presence of an oleic acid stabilizer and oleylamine [27].
SiO2 coating on the Fe3O4 NPs was performed through
the formation of water-in-cyclohexane reverse microe-
mulsion [28] (Figure 1).
Polyoxyethylene(5) nonylphenyl ether (5 mL, Igepal
CO-520, Sigma-Aldrich, St. Louis, MO, USA) was firstly
dispersed in cyclohexane (40 mL). Then, 2 mL Fe3O4
solution (50 mg mL−1 in cyclohexane) was added. After
10 min, ammonium hydroxide (292 μL) was added to form
a transparent brown solution of reverse microemulsion.Figure 1 Synthesis of Fe3O4@SiO2-OCMCS-FA.Next, tetraethylorthosilicate (TEOS) was added and the
reaction was continued at room temperature for 24 h.
When isopropanol was added into the reaction solution,
Fe3O4@SiO2 NPs were precipitated. They were collected
by centrifugation and washed with ethanol. Fe3O4@SiO2
NPs were then dried in vacuum at 60°C.
Synthesis of OCMCS-FA conjugate
The synthesis of OCMCS-FA conjugate was adopted by
homogeneous synthesis through acylation (Figure 2).
Folic acid (0.884 g) was dissolved in 20 mL of anhydrous
dimethylsulfoxide (DMSO) to which dicyclohexylcarbo-
diimide (DCC; 0.784 g) and N-hydroxysuccinimide (NHS;
0.256 g) were added. The reaction mixture was stirred for
24 h at 45°C in the dark [29]. The by-product dicyclo-
hexylurea was filtered off, and 20 mL of 30% acetone in
diethyl ether was added with stirring. A yellow precipitate
(NHS-FA) formed and was collected after washing with
diethyl ether several times. Then, 100 mg OCMCS was
dissolved in acetate buffer (pH 4.7). A mixture solution of
NHS-FA and 1-ethyl-3-(3-dimethylaminopropyl) carbodii-
mide (EDC) was prepared by dissolving NHS-FA and
EDC simultaneously in DMSO. Finally, the mixture solu-
tion was dropped into the OCMCS solution. After 24 h,
the solution was adjusted to pH 9 with NaOH and puri-
fied by centrifugation followed by 2 days of dialysis against
phosphate-buffered solution (PBS) and extensive dialysis
against water using a 3,500-Da cutoff dialysis membrane.
OCMCS-FA was then dried in vacuum at 60°C.
Synthesis of Fe3O4@SiO2-OCMCS-FA NPs
APTES was anchored to the surface of Fe3O4@SiO2
through refluxing at 110°C in toluene to develop amide in
the surface of silica in order to introduce carboxyl groups
of OCMCS-FA conjugate. Fifty milligrams of APTES-
modified Fe3O4 was added to 10 mL of a 2-(N-morpholino)
ethanesulfonic acid buffer (0.1 M, pH 6.5) containing
50 mg of OCMCS-FA, EDC (20 mM), and NHS (50 mM).
The mixture suspension was then sonicated for 10 min
in ultrasonic disrupter and shaken for 24 h at room
temperature. The OCMCS-FA bound Fe3O4@SiO2 were
collected under centrifugation, washed with ethanol,
and dried in vacuum at 60°C.
Figure 2 Synthesis of OCMCS-FA.
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Two milliliters of rat blood was injected from the eye
socket vein. The red blood cells (RBCs) were obtained
by removing the serum from the blood by centrifugation
and suction. After being washed with PBS solution five
times, the RBCs were diluted to 1/10 of their volume
with PBS solution. Diluted RBC suspension (0.3 mL)
was then mixed with the following: (a) PBS (1.2 mL) as a
negative control, (b) deionized water (1.2 mL) as a posi-
tive control, and (c) nanovehicle suspensions (1.2 mL) at
concentrations ranging from 40 to 500 μg mL−1. The
mixtures were then vortexed and kept for 2 h at room
temperature. Finally, the mixtures were centrifuged for
2 min at 4,000 rpm and the absorbance of the upper
supernatants at 541 nm was measured by UV-visible
(UV-vis) characterization. The percentage of hemolysis
was calculated using the following equation (A is the
absorbance of UV-vis spectra) [30]:
Hemolysis ¼ Asample−A −ð Þcontrol
 
= A þð Þcontrol−A −ð Þcontrol
 
Cell culture and uptake
HeLa cell lines were maintained in Dulbecco's modified
Eagle's medium (DMEM) containing 10% fetal bovine
serum, 100 units mL−1 penicillin, and 100 mg mL−1
streptomycin in 37°C, 5% CO2. For investigation on tar-
geting of nanovehicles, nanovehicles were labeled with
RB to form RBFe3O4@SiO2 and RBFe3O4@SiO2-
OCMCS-FA nanoparticles [31]. In a typical procedure,
2.5 × 104 cells were seeded in a 35-mm dish with aglass bottom for 24 h to allow the cells to attach.
After the cells were washed twice with PBS, the sam-
ples were added to the dishes in a concentration of
100 μg mL−1. After 2 h of incubation, the cells were
washed several times with PBS to remove the
remaining samples and dead cells. Finally, the cells
were observed under a confocal laser scanning microscope
(CLSM; Carl Zeiss LSM 710, Oberkochen, Germany).
Cells with the addition of Fe3O4@SiO2 were imaged as
control.Bio-TEM observations for HeLa cells
The HeLa cells were incubated with 2.5 μg mL−1 nano-
vehicle inDMEM in 5% CO2 at 37°C for 24 h. After-
wards, cells were washed three times with PBS and
subsequently fixed with 2.5% glutaraldehyde in 0.03 M
potassium phosphate buffer for at least 24 h. Cells
were then washed in PBS, postfixed with 1% osmium
tetroxide in sodium carboxylate buffer, washed with
0.05 mol L−1 maleate, and stained with 0.5% uranylace-
tate (Sigma-Aldrich) in maleate buffer. After washing the
cells in 0.05 mol L−1 maleate, the cells were dehydrated in
a grading series of ethanol followed by acetone, embedded
in Epon (Momentive Specialty Chemicals, Inc., Columbus,
OH, USA), and dried in an oven at 60°C for 4 days. Ultra-
thin sections of approximately 50 nm thick were cut with
a diamond knife on a Leica Ultracut R ultramicrotome
(Milton Keynes, UK) and transferred to the copper grid.
The images were viewed on JEOL-2100 electron micro-
scope (Akishima, Tokyo, Japan).
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The in vitro cytotoxicity was measured by using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT) assay in HeLa cells. Cells were initially seeded
into a 96-well cell culture plate at 1 × 104 per well and
then incubated for 24 h at 37°C under 5% CO2. DEME so-
lutions of nanovehicle at concentrations of 100 mg mL−1
were added to the wells. The cells were further incubated
for 72 h at 37°C under 5% CO2. The cells were washed
three times with 0.2 mL PBS to remove the unbound
nanoparticles. Subsequently, 0.2 mL DEME and 25 mL
MTT (5 mg mL−1) were added to each well and incubated
for an additional 4 h at 37°C under 5% CO2. Then, the
medium solution was replaced by 0.15 mL DMSO solu-
tion. After 10 min, the optical density at 490 nm (absorp-
tion value) of each well was measured on a Tecan Infinite
M 200 monochromator-based multifunction micro-
plate reader (Männedorf, Switzerland). The correspond-
ing nanovehicle with cells but not treated by MTT were
used as controls. The cell vitality after labeling was com-
pared with that of unlabeled cells and expressed as the
relative ratio.
Characterization
1H NMR spectra was recorded at 300 MHz on a Bruker
ARX 300 spectrometer (Ettlingen, Germany). Infrared
spectra (4,000 to 400 cm−1) were recorded on Bruker
Fourier transform infrared (FTIR) spectrometer in KBr
pellets. The X-ray powder diffraction patterns were
recorded on an X'Pert diffractometer (PANalytical B.V.,
Almelo, The Netherlands) with CuKα radiation (λ =
1.54060 Å) at 45 kV and 40 mA. X-ray photoelectron
spectroscopy (XPS) analysis was performed with a ESCALB
MK-II (Physical Electronics Instruments, Chanhassen, MN,Figure 3 1H NMR spectra of OCMCS-FA in CF3COOD/D2O.USA). The source was the monochromatic MgKα radiation.
The surface charge of the nanovehicles was investigated on
Malvern Zetasizer Nano ZS 90 zeta potential analyzer
(Westborough, MA, USA). Transmission electron micros-
copy (TEM) was performed on a JEOL-2100 with an
accelerating voltage of 200 kV. TEM samples were
prepared by drop-casting dispersion onto copper grids
covered by carbon film. Ultrathin sections for bio-
TEM were cut with a diamond knife on a Leica Ultracut R
ultramicrotome. Scanning electron microscopy (SEM)
was performed on a JEOL-S-3400 N II. Magnetic
property measurements were performed using a Quantum
Design MPMS XL-7 superconducting quantum interference
device (SQUID; Olomouc, Czech Republic). Confocal
images were acquired using a Zeiss confocal laser
scanning unit mounted on an LSM 710 fixed-stage
upright microscope.
Results and discussion
The 1H NMR spectra of OCMCS-FA conjugate was
shown in Figure 3. The signals at δ 1.65, 2.88, and 3.08
to 3.64 ppm was assigned to the resonance of the
monosaccharide residue protons, -COCH3, -CH-NH-,
and -CH2-O-, respectively. The signals appearing at δ
6.3 to 8.5 ppm were attributed to the resonance of the
folate aromatic protons. So, it revealed that the couple
of the FA residue to the OCMCS could be achieved via
EDC mediation [32].
FTIR spectroscopy shown in Figure 4 confirmed
that OCMCS-FA was successfully immobilized on the
Fe3O4@SiO2 NPs. In the spectrum of OCMCS-FA
(Figure 4b), the 1,635 cm−1 peak of COO- stretching
vibration shifted to 1,590 cm−1 compared to OCMCS
(Figure 4a). Moreover, a shoulder peak around 1,710 cm−1
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gated to the OCMCS successfully [33]. The bare Fe3O4
NPs showed characteristic bands related to the Fe-O
vibrations near 569 cm−1 (Figure 4b,c). The peak at
1,100 cm−1 indicated Si-O bonding on the NP surface
(Figure 4c). Unsurprisingly, the FTIR spectra for Fe3O4@-
SiO2-OCMCS-FA nanovehicle presented similar peaks at
1,710, 1,590, 1,100, and 569 cm−1 (Figure 4d). What is
more, the FTIR spectrum of Fe3O4@SiO2-OCMCS-FA
nanovehicle displayed an intense peak at 1,650 cm−1
which might result from the -CONH- due to the reaction
between the carboxyl group of the OCMCS and amide on
the surface of silica.
The XRD measurements were performed with the
dried powder samples of bare, silica-coated and
OCMCS-FA-conjugated iron oxide to identify the crystal
phases. The pattern of OCMCS-FA-conjugated NPs
(Figure 5) showed all the major peaks corresponding to
Fe3O4 which could be assigned to the (311), (511), and
(440) planes, respectively [34]. Additionally, the peak
around 2θ = 25° due to the silica [35] was observed in
the case of the silica-coated NPs, but disappeared in
the Fe3O4@SiO2-OCMCS-FA nanovehicle which may
attribute to the OCMCS-FA conjugated. These results
confirmed the surface modification of the Fe3O4 NPs
with OCMCS-FA.
The surface composition was also ascertained by XPS as
it is recognized as a quantitative surface elemental analysis
and chemical state information. Wide-scan spectra were
acquired for NPs with high-resolution C 1s, O 1s, and N
1s. Spectral calibration was carried out by setting the
main C 1s peak at 285 eV. The high-resolution scans forFigure 4 FTIR spectra. (a) OCMCS, (b) OCMCS-FA, (c) Fe3O4@SiO2, and (dC 1s (Figure 6a) of Fe3O4@SiO2-OCMCS-FA nanovehicle
could be deconvoluted into four peaks at 285.7,
284.5, 286.3, and 288.2 eV, which could be attributed
to -C-O-, -C-C-, -NH-C = O, and -COOH groups, re-
spectively. The O 1 s spectrum (Figure 6b) of nanove-
hicle displayed three peaks at 532.3, 532.6, and 530.9 eV
corresponding to oxygen being present in three different
environments as -C-O, -O-H, and C =O in Fe3O4@SiO2-
OCMCS-FA nanovehicle. Compared with the free folate,
OCMCS-FA, and Fe3O4@SiO2-OCMCS-FA, distinction
was made towards the high-resolution scans for N 1s. Free
folate (Figure 6e) could be deconvoluted into four peaks
at 399. 9, 400.1, 399.5, and 398.5 eV. The bands at 398.5
and 399.5 eV are due to the amide N and other N of FA,
respectively. The bands at 400.1 and 399.9 eV were in ac-
cordance with those of triazole ring N as reported [36].
However, the peak of free amide N at 398.5 eV disap-
peared in the spectrum of OCMCS-FA (Figure 6d), and
a new peak at 400.8 eV appeared due to the amide con-
jugation between FA and OCMCS. Interestingly, the
N 1-s spectrum of Fe3O4@SiO2-OCMCS-FA nanovehicle
(Figure 6c) showed similar peaks with OCMCS-FA except
at 401.2 eV. The peak at 401.2 eV might be originated
from the formation of amide linkage between the carboxyl
group of the OCMCS and amide on the surface of silica
which was reasonably consistent with the peak reported in
the literature. Anyway, XPS results support OCMCS-
FA chemically bound to the surface of Fe3O4@SiO2
by amidation.
Moreover, the zeta potential of suspension for
Fe3O4@SiO2-OCMCS-FA was −28.89 ± 0.43 mV which
was smaller than that of Fe3O4 NPs considering that) Fe3O4@SiO2-OCMCS-FA.
Figure 5 XRD spectrum. (a) Fe3O4 NPs, (b) Fe3O4@SiO2, (c) Fe3O4@SiO2-FA, and (d) Fe3O4@SiO2-OCMCS-FA.
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NPs away from aggregation. As shown in Figure 7,
spherical Fe3O4 NPs were chosen as the template to
obtain multifunctional nanovehicle. It can be seen
that spherical Fe3O4 NPs were about 6 to 8 nm in
size with high dispersibility (Figure 7a, inset). The
corresponding high-resolution image (Figure 7a, inset)Figure 6 High-resolution C 1s, O 1s, and N 1s X-ray photoelectron sp
(b) high-resolution O 1s spectrum of Fe3O4@SiO2-OCMCS-FA, (c) high-reso
N 1s of OCMCS-FA, and (e) high-resolution N 1s spectrum of FA.showed clear lattice fringes which corresponds to
Fe3O4. A thick layer of dense silica was deposited
onto the surface of Fe3O4 with a core thickness of
7 nm and shell thickness of 14 nm (Figure 7a) with
uniform particle size and excellent morphology. Then,
a thin layer of OCMCS-FA conjugated to the surface
of Fe3O4@SiO2 through amidation with the aid ofectra. (a) High-resolution C 1s spectrum of Fe3O4@SiO2-OCMCS-FA,
lution N 1s spectrum of Fe3O4@SiO2-OCMCS-FA, (d) high-resolution
Figure 7 TEM images. (a) Fe3O4@SiO2 (inset: Fe3O4) and (b) Fe3O4@SiO2-OCMCS-FA (inset: SEM images of Fe3O4@SiO2-OCMCS-FA).
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(5 nm) multifunctional nanovehicle (Fe3O4@SiO2-
OCMCS-FA) (Figure 7b). The SEM image shows that
the nanovehicles are very uniform in both size and
shape (Figure 7b, inset).
The magnified hysteresis loop of Fe3O4@SiO2-
OCMCS-FA nanovehicle which clearly showed that no
remanence and hysteresis were detected demonstrated
the superparamagnetism of the nanovehicle (Figure 8).
After coating with silica, the magnetization of Fe3O4@SiO2
was undoubtedly decreased compared with the Fe3O4
nanoparticles for the shell and relatively low Fe3O4
amount. However, after the final modification of
OCMCS-FA, the magnetization of the nanovesicles was
not apparently decreased due to the thin outer layer.
Factually, superparamagnetism is usually highly desired
because it can prevent the magnetic composite parti-
cles from irreversible aggregation and ensure anFigure 8 Magnetization curve. (a) Fe3O4 (b) Fe3O4@SiO2, and (c) Fe3O4@excellent dispersibility once the applied magnetic field
is removed [37].
In vitro targeting of nanovehicle
The ability of nanoparticles to target specific locations
is one of the most important factors for their pro-
spective application in drug delivery and biomedicine. To
investigate the uptake possibility of Fe3O4@SiO2-
OCMCS-FA, CLSM was applied to trace the process of
this nanovehicle. Therefore, RB is labeled on the surface
of the nanovehicle to distinguish it. To explore the prac-
tical application of this nanovehicle in the targeting of
tumor cells, the particles were incubated in physiological
conditions with HeLa cells bearing the over-expressed fol-
ate receptor. Figure 9 shows DAPI, RB, and merged im-
ages of HeLa cells incubated with RBFe3O4@SiO2
(20 μg mL−1, control) and RBFe3O4@SiO2-OCMCS-FA
(20 μg mL−1) for 2 h. Interestingly, even at the very lowSiO2-OCMCS-FA nanovehicle at 300 K.
Figure 9 Confocal laser scanning microscope images of subcellular localization. (a) RBFe3O4@SiO2 and (b) RBFe3O4@SiO2-OCMCS-FA after
2 h of incubation with HeLa cells. Nuclei were stained with DAPI.
Figure 10 Bio-TEM images of HeLa cells after 24 h of exposure to NPs (100 μg mL−1). (a) Control, (b) Fe3O4@SiO2-OCMCS-FA nanovehicle
(inset: magnified image of the circled area) and (c, d) magnified image of Fe3O4@SiO2-OCMCS-FA nanovehicle.
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Figure 11 Percentage of hemolysis of RBCs in the presence of Fe3O4@SiO2-OCMCS-FA at 500 μg mL
−1. Water (+) and PBS (−) are used as
positive and negative controls, respectively.
Figure 12 Cell inhibition of Fe3O4@SiO2-OCMCS-FA nanovehicle
on HeLa and L-O2 cells.
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RBFe3O4@SiO2-OCMCS-FA nanoparticles could be taken
up by HeLa cells within a short period as manifested by
the appearance of spot-like red fluorescence in cells
(Figure 9b), while untreated RBFe3O4@SiO2 showed negli-
gible background fluorescence under similar imaging con-
ditions (Figure 9a). The merge of the bright-field and
fluorescent images further demonstrates that the lumines-
cence is strongly correlated with the intracellular location
(Figure 9b) suggesting the feasibility and efficiency of the
nanoparticles for anticancer drug delivery into cancer
cells. In addition, the fluorescent image shown in Figure 9b
also testifies that the nanovehicle was mainly distributed
in the cytoplasm after cellular uptake. The confocal laser
scanning microscope observation confirms that the nano-
vehicle could be effectively taken up by the HeLa cells as
the folate modified.
To further reveal that the nanovehicle was internal-
ized in HeLa cells rather than being bound to the cell
surface, bio-TEM was used to analyze the
nanovehicle-treated cells. Unlike the untreated cells
(Figure 10a), some aggregates of nanovehicles were
observed as black patches inside the cell cytoplasm
which maintained their core-shell structure (Figure 10b
and the inset), while no nanovehicle was found in the
nucleus which coincided with the results of CLSM.
Based on the cell morphology, it is plausible that the
nanovehicle accumulates on the membrane (Figure 10c)
by the high specific interaction between folic acid on the
nanovehicle and FR on HeLa cells which may increase the
uptake through folate receptor-mediated endocytosis.
Afterwards, majority of the internalized nanovehicle willbe processed in lysosomes and are eventually released
into the cytoplasm (Figure 10d). Therefore, in vitro
CLSM and bio-TEM images present evidence about the
target effects of nanovehicle with the OCMCS-FA
modification.
Biocompatibility of nanovehicles (hemolysis assay and
cytotoxicity)
It is important to investigate the biocompatibility of
Fe3O4@SiO2-OCMCS-FA nanovehicles when materials
are administrated by vein injection. Hemolysis assay is a
primary approach to assess the biocompatibility for in vivo
applications. The hemolysis percentage of the nanovehicles
was quantified based on the absorbance of the supernatant
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From Figure 11, Fe3O4@SiO2-OCMCS-FA nanovehicle ex-
hibits good biocompatibility, and the hemolysis percentage
of Fe3O4@SiO2-OCMCS-FA even at a high concentration
of 500 μg mL−1 was 6.3% lower than the value of trad-
itional nanoparticles (70% of 500 μg mL−1) [38]. Thus,
the obtained results showed that no visible hemolysis ef-
fect was observed visually for nanovehicle to evidence
the good blood compatibility for the introduction of
OCMCS.
In order to verify the toxicity of nanovehicle, in vitro
cytotoxicity of the nanovehicle on HeLa and human liver
cells (L-O2) was evaluated using a traditional MTT assay.
The results (Figure 12) showed that there was a relatively
high cell viability (more than 80% at a concentration of
100 μg mL−1) in HeLa which displays low cytotoxicity and
favorable cell compatibility which is consistent with
hemolysis assay. In addition, the viability of the L-O2 cells
was similar to that of the HeLa after incubating with
nanovehicle which demonstrates that Fe3O4@SiO2-
OCMCS-FA possesses safety for normal cells as a drug
carrier. The mesoporous silica layer of this nanovehicle is
currently studied by our group, which may offer the plat-
form for insoluble drugs in biomedical application.Conclusions
In summary, we presented a rational method of prepar-
ing folic acid-conjugated carboxymethyl chitosan by
homogeneous synthesis characterized by 1H NMR and
FTIR. Moreover, a novel, safe, and tumor-targeting
nanovehicle with iron oxide as core and silica as shell
has been fabricated showing good dispersion. It was
firstly reported that OCMCS-FA conjugated on the sur-
face of Fe3O4@SiO2 via amide reaction to form the
layer of compatibility and receptor-mediated targeting.
Fe3O4@SiO2-OCMCS-FA nanovehicle exhibits high up-
take of HeLa cells which imply low cytotoxicity and good
biocompatibility because of the dual targeting and
OCMCS serving as a long circulation. Furthermore, the
silica moiety of Fe3O4@SiO2-OCMCS-FA nanovehicle
could be extended to fabricate mesoporous nanovehicle
which may increase surface area and pore volume. Thus,
we believe that this strategy may provide a safe and effi-
cient platform for antitumor drug delivery.Competing interests
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